Skip to main content
logo
Intra-Cellular Therapies, Inc. (ITCI)
Apr 2, 2024 - ITCI was delisted (reason: acquired by JNJ)
131.87
0.00 (0.00%)
Inactive · Last trade price on Apr 1, 2025

Intra-Cellular Therapies Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
680.85464.37250.3183.822.81
Revenue Growth
46.62%85.52%198.69%267.35%37537.14%
Cost of Revenue
293.08213.89155.1696.8867.68
Gross Profit
387.77250.4895.16-13.08-44.86
Selling, General & Admin
504.49409.86358.78272.61186.36
Operating Expenses
504.49409.86358.78272.61186.36
Operating Income
-116.72-159.38-263.63-285.69-231.23
Interest & Investment Income
42.5220.347.381.574.24
Pretax Income
-74.2-139.04-256.25-284.12-226.99
Income Tax Expense
0.470.640.010.010.01
Net Income
-74.68-139.67-256.26-284.13-227.01
Net Income to Common
-74.68-139.67-256.26-284.13-227.01
Net Income Growth
-----
Shares Outstanding (Basic)
10396948170
Shares Outstanding (Diluted)
10396948170
Shares Change
7.56%1.95%15.75%15.47%27.50%
EPS (Basic)
-0.72-1.46-2.72-3.50-3.23
EPS (Diluted)
-0.72-1.46-2.72-3.50-3.23
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Free Cash Flow
-73.5-124.47-270.96-259.87-230.34
Free Cash Flow Per Share
-0.71-1.30-2.88-3.20-3.27
Gross Margin
56.95%53.94%38.02%-15.60%-196.66%
Operating Margin
-17.14%-34.32%-105.32%-340.90%-1013.58%
Profit Margin
-10.97%-30.08%-102.37%-339.04%-995.07%
Free Cash Flow Margin
-10.79%-26.80%-108.25%-310.10%-1009.69%
EBITDA
-116.21-158.85-262.97-285.16-230.7
EBITDA Margin
-17.07%-34.21%-105.06%--
D&A For EBITDA
0.510.530.660.530.53
EBIT
-116.72-159.38-263.63-285.69-231.23
EBIT Margin
-17.14%-34.32%-105.32%--
Revenue as Reported
680.85464.37250.3183.822.81
Advertising Expenses
101.292.285.882.536.3
SEC Filings: 10-K · 10-Q